Acumen Pharmaceuticals, Inc.

NasdaqGS:ABOS 주식 보고서

시가총액: US$149.0m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Acumen Pharmaceuticals 관리

관리 기준 확인 2/4

Acumen Pharmaceuticals' CEO는 Dan O'Connell, Dec2014 에 임명되었습니다 의 임기는 9.5 년입니다. 총 연간 보상은 $ 3.93M, 15.2% 로 구성됩니다. 15.2% 급여 및 84.8% 보너스(회사 주식 및 옵션 포함). 는 $ 59.38K 가치에 해당하는 회사 주식의 0.042% 직접 소유합니다. 59.38K. 경영진과 이사회의 평균 재임 기간은 각각 2.6 년과 5.7 년입니다.

주요 정보

Dan O'Connell

최고 경영자

US$3.9m

총 보상

CEO 급여 비율15.2%
CEO 임기9.8yrs
CEO 소유권0.04%
경영진 평균 재임 기간2.9yrs
이사회 평균 재임 기간6yrs

최근 관리 업데이트

Recent updates

Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?

Aug 05
Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?

Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's

Jul 30

Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?

Apr 21
Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?

Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

Sep 21
Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Feb 01
We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 16
Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Acumen Pharma at 11-month high on rivals’ Alzheimer’s data

Sep 28

Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate

Jun 30

We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

May 10
We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Jan 07
We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 01
Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

CEO 보상 분석

Dan O'Connell 의 보수는 Acumen Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$65m

Mar 31 2024n/an/a

-US$56m

Dec 31 2023US$4mUS$598k

-US$52m

Sep 30 2023n/an/a

-US$49m

Jun 30 2023n/an/a

-US$46m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$3mUS$570k

-US$43m

Sep 30 2022n/an/a

-US$38m

Jun 30 2022n/an/a

-US$32m

Mar 31 2022n/an/a

-US$83m

Dec 31 2021US$1mUS$525k

-US$101m

Sep 30 2021n/an/a

-US$93m

Jun 30 2021n/an/a

-US$92m

Mar 31 2021n/an/a

-US$32m

Dec 31 2020US$336kUS$240k

-US$7m

보상 대 시장: Dan 의 총 보상 ($USD 3.93M )은 US 시장( $USD 683.56K ).

보상과 수익: 회사가 수익성이 없는 동안 Dan 의 보상이 증가했습니다.

CEO

Dan O'Connell (54 yo)

9.8yrs

테뉴어

US$3,930,011

보상

Mr. Daniel J. O’Connell, also known as Dan, MBA was a Key Advisor at Acidophil, LLC. He served as President until February 01, 2024 and serves as Chief Executive Officer of Acumen Pharmaceuticals, Inc. si...

리더십 팀

이름위치테뉴어보상소유권
Daniel O'Connell
CEO & Director9.8yrsUS$3.93m0.042%
$ 63.2k
Matt Zuga
CFO & Chief Business Officer3.4yrsUS$1.61m0.14%
$ 206.1k
Derek Meisner
Chief Legal Officer & Corporate Secretary2.1yrsUS$1.48m0%
$ 0
James Doherty
President & Chief Development Officerless than a year데이터 없음데이터 없음
Grant Krafft
Co-Founder28.8yrsUS$42.00k데이터 없음
Caleb Finch
Co-Founderno data데이터 없음데이터 없음
William Klein
Co-Founderno data데이터 없음데이터 없음
Russell Barton
Chief Operating Officer3.8yrsUS$223.68k0.16%
$ 240.2k
Kelly Carranza
Vice President1.3yrs데이터 없음데이터 없음
Alex Braun
VP & Head of Investor Relations2.1yrs데이터 없음데이터 없음
Robyn Moxon
Associate Director of Communications2.4yrs데이터 없음데이터 없음
Julie Bockenstette
Executive VP & Head of Human Resources3.8yrs데이터 없음데이터 없음

2.9yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: ABOS 의 관리팀은 경험 ( 2.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Daniel O'Connell
CEO & Director18.5yrsUS$3.93m0.042%
$ 63.2k
Michael Weiner
Member of Clinical & Scientific Advisory Boardno data데이터 없음데이터 없음
Colin Masters
Member of Clinical & Scientific Advisory Boardno data데이터 없음데이터 없음
Jeffrey Cummings
Member of Clinical & Scientific Advisory Boardno data데이터 없음데이터 없음
Sean Stalfort
Independent Chairman of the Board6yrsUS$173.52k0.51%
$ 753.7k
Kimberlee Drapkin
Independent Director2.5yrsUS$152.27k0%
$ 0
Steven DeKosky
Member of Clinical & Scientific Advisory Boardno data데이터 없음데이터 없음
Jeffrey L. Ives
Independent Director10.4yrsUS$141.02k0%
$ 0
Reisa Sperling
Member of Clinical & Scientific Advisory Boardno data데이터 없음데이터 없음
Cynthia Lemere
Member of Clinical & Scientific Advisory Boardno data데이터 없음데이터 없음
Laura Stoppel
Independent Director3.9yrsUS$147.52k0%
$ 0
Stephen Salloway
Member of Clinical & Scientific Advisory Boardno data데이터 없음데이터 없음

6.0yrs

평균 재임 기간

64.5yo

평균 연령

경험이 풍부한 이사회: ABOS 의 이사회는 경험(평균 재직 기간 5.7 년)으로 간주됩니다.